4.7 Article

T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity

Journal

JCI INSIGHT
Volume 7, Issue 10, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.150070

Keywords

-

Funding

  1. Adaptive Biotechnologies
  2. Frederick National Laboratory for Cancer Research, NIAID [75N91019D00024]
  3. NIAID [75N93019C0063]
  4. NIAID, NIH
  5. US Department of Health and Human Services (DHHS) [HHSN272201800013C]
  6. Fred Hutchinson Joel Meyers Endowment
  7. Fast-Grants
  8. American Society for Transplantation and Cell Therapy
  9. [AI118916]
  10. [AI104002]
  11. [AI115296]

Ask authors/readers for more resources

This study suggests that measuring T cell responses can provide reliable assessment of past SARS-CoV-2 infection and protective immunity. T cell responses showed significant correlations with neutralizing antibody titers and disease severity indicators. T cell testing demonstrated high sensitivity even after 6 months of infection, outperforming serology tests in identifying prior infection, especially in individuals with milder disease.
BACKGROUND. Measuring the immune response to SARS-CoV-2 enables assessment of past infection and protective immunity. SARS-CoV-2 infection induces humoral and T cell responses, but these responses vary with disease severity and individual characteristics. METHODS. A T cell receptor (TCR) immunosequencing assay was conducted using small-volume blood samples from 302 individuals recovered from COVID-19. Correlations between the magnitude of the T cell response and neutralizing antibody (nAb) titers or indicators of disease severity were evaluated. Sensitivity of T cell testing was assessed and compared with serologic testing. RESULTS. SARS-CoV-2-specific T cell responses were significantly correlated with nAb titers and clinical indicators of disease severity, including hospitalization, fever, and difficulty breathing. Despite modest declines in depth and breadth of T cell responses during convalescence, high sensitivity was observed until at least 6 months after infection, with overall sensitivity similar to 5% greater than serology tests for identifying prior SARS-CoV-2 infection. Improved performance of T cell testing was most apparent in recovered, nonhospitalized individuals sampled >150 days after initial illness, suggesting greater sensitivity than serology at later time points and in individuals with less severe disease. T cell testing identified SARS-CoV-2 infection in 68% (55 of 81) of samples with undetectable nAb titers (<1:40) and in 37% (13 of 35) of samples classified as negative by 3 antibody assays. CONCLUSION. These results support TCR-based testing as a scalable, reliable measure of past SARS-CoV-2 infection with clinical value beyond serology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available